Hyperlipidaemia, or high blood lipid levels, is a significant risk factor for cardiovascular diseases. Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Tirzepatide is indicated for patients with type 2 diabetes and adults with obesity and overweight to reduce body weight. In recent years, there have been reports that this drug also has beneficial effects on the lipid profile. This paper summarizes data from the SURMOUNT clinical trials to evaluate how tirzepatide affects lipid profile parameters. The analysis demonstrated numerous benefits resulting from tirzepatide therapy. The observed favourable safety profile additionally enhances the attractiveness of this drug as a therapy for individuals with lipid disorders. Tirzepatide could be a breakthrough drug not only for obesity and type 2 diabetes but also for dyslipidaemia. However, despite promising results, further research is needed to understand the long-term safety and cost implications associated with this agent. These studies will be crucial for developing individualized therapeutic plans and optimizing the use of tirzepatide in various patient subgroups.